Stock·NYSE·Healthcare
Zimmer Biomet Holdings Inc. (ZBH)
- Market cap
- $18.33B
- P/E
- 22.40
- Dividend yield
- 1.00%
- Street target
- $105.00median of 27 analysts
- 52-week range
- $79.12 $103.70
ZBH stock forecast today
Where ZBH stands today, and what CleaRank Financial AI makes of it.
ZBH at a glance
Zimmer Biomet Holdings Inc. (ZBH): Buy, 70/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($95.06 and $91.53).
- Earnings ZBH beat estimates in 6 of the 7 reports in our data, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $2.2M and made no open-market purchases over the last 18 months.
- Valuation P/E of 22.4 against 31.9 for the Healthcare sector: a discount to peers (-30%).
Figures as of October 27, 2026.
CleaRank Financial AI
CleaRank rates Zimmer Biomet Holdings Inc. (ZBH) Buy, with a model score of 70/100.
Valuation lifts the score most: the P/E of 22.40 is 29.8% below the sector median (a discount to peers) and the P/S of 2.15 is 36.8% below the sector median. Revenue growth holds it back most: revenue grew 4.80%, 3.3 percentage points slower than the sector median. The trend is up: ZBH trades 1.08% above its 50-day average of $95.06 and 4.97% above its 200-day average of $91.53. Over the past year the price fell 6.83%.
Only on CleaRank
Figures we compute ourselves from ZBH's own price, earnings and insider-filing history. Tap one to see it in context.
ZBH stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $96.08 is 1.1% above the 50-day simple moving average of $95.06.Price above its 200-day average ›
The price is 5.0% above the 200-day simple moving average of $91.53.50-day average above the 200-day ›
The 50-day average ($95.06) is 3.8% above the 200-day average ($91.53), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 69% of its 52-week range, between $79.12 and $103.70.
ZBH share price
Pick a period: each tab shows how far ZBH has moved over it, to the last close.
Today's trading
Where ZBH sits inside today's range and its 52-week range.
ZBH fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 22.40 is 29.8% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 2.15 is 36.7% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $806.7M on revenue of $8.5B, a net margin of 9.5%.Beat estimates in most recent reports ›
ZBH beat the EPS estimate in 6 of the 7 reports in our data.Pays a dividend ›
The trailing dividend yield is 1.00%, or $0.96 a share a year.
Key statistics
The headline figures for ZBH.
As of October 27, 2026, ZBH trades at $96.08, with a market value of $18.33B, a P/E ratio of 22.40 and a dividend yield of 1.00%.
What the numbers say
CleaRank Financial AI's reading of ZBH's valuation, growth and risks.
Against the 31.9 median P/E of Healthcare stocks, ZBH's P/E of 22.40 is 29.8% below that median, which counts as a discount to peers. ZBH trades at 2.15 times its sales, 36.8% below the sector median of 3.4. ZBH has a market capitalisation of $18.3B and trailing earnings of $4.29 a share.
With revenue growth of 4.80%, ZBH is 3.3 percentage points slower than the sector median of 8.1%. The business earns a net margin of 9.48% and an operating margin of 17.96% and a return on equity of 6.41%, below the sector median of 7.3%. The balance sheet and payout round out the picture, with debt-to-equity of 0.60 and a trailing dividend yield of 1.00% ($0.96 a share a year).
The August 5, 2026 report delivered adjusted EPS of $2.07, which topped the $2.01 analyst estimate by 2.99%. Even so, the share price dropped 0.99% in the following session.
ZBH has topped the EPS estimate in 6 of the 7 reports in our data, yet those beats have not reliably lifted the shares: the stock fell the next session after 3 of them. For this fiscal year, analysts average an EPS estimate of $8.54, growth of 4.1%, and $9.05 for next year, which would be growth of 6.1%.
ZBH typically moves about 1.83% in a day, and its beta against the S&P 500 is 0.49. Over the last 18 months insiders sold $2.2M of stock and purchased none on the open market. Such sales are frequently scheduled ahead of time, so they tell an investor less than buying would.
ZBH against the Healthcare sector
How ZBH compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: ZBH trades at a notable discount to sector peers (-30%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 14, 2025, ZBH has gained 2.2% against a gain of 39.2% for XLV.
Performance against XLV
ZBH and the Healthcare sector fund over the same days.
Revenue and earnings
How much ZBH sells, and how much of it becomes profit.
Revenue growth: Revenue grew 7.2% in FY2025 to $8.2B, from $7.7B a year earlier.
Profit margin: The net margin was 8.6% in FY2025, down from 11.8% the year before.
Profitable: ZBH earned $705M in FY2025.
Earnings reality check
Did ZBH beat what analysts expected, and how did the stock react?
Earnings record: ZBH beat the analyst estimate in 6 of the 7 reports in our data.
Market reaction: The stock fell in the first session after 3 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 5, 2026after close | $2.01 | $2.07 | +2.99% | -0.99% | -0.28% |
| Apr 28, 2026after close | $1.86 | $2.09 | +12.37% | -3.30% | +0.25% |
| Nov 5, 2025after close | $1.87 | $1.90 | +1.60% | +1.10% | +2.83% |
| Aug 7, 2025after close | $1.98 | $2.07 | +4.55% | +0.84% | +3.75% |
| May 5, 2025after close | $1.77 | $1.81 | +2.26% | +1.98% | +8.55% |
| Feb 6, 2025after close | $2.29 | $2.31 | +0.87% | -1.71% | -2.71% |
| Oct 30, 2024after close | $1.74 | $1.74 | +0.00% | -2.63% | +0.33% |
As of October 27, 2026, ZBH has beaten the analyst EPS estimate in 6 of the 7 reports in our data and fell in the first trading session after 3 of those beats; its latest report, on August 5, 2026, came in 2.99% above the estimate and the stock moved -0.99% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
ZBH AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 55.5, in neutral territory.RSI above 50 ›
An RSI of 55.5 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of ZBH
The score, the reasoning behind it, and what could move the price next.
ZBH, the company also known as Zimmer Biomet Holdings Inc., changed hands at $96.08 and sits above both its key moving averages. The price is 1.08% above its 50-day average of $95.06 and 4.97% above its 200-day average of $91.53. The 50-day average is 3.85% above the 200-day, a configuration that backs up the upward move. Inside its 52-week range of $79.12 to $103.70, the stock stands at 69% of the way up, and the price is 7.35% below the high.
Recent gains sit against a weaker longer record: the price rose 5.54% over the past month, rose 0.34% over the past three months and fell 6.83% over the past year. The 14-day RSI of 55.5 is in the neutral zone, and the MACD line is positive.
Rating reaffirmed ›
Argus Research kept its Buy rating on October 22, 2026.
Source: Analyst action, Argus Research, October 22, 2026
Earnings beat, but the stock fell ›
The August 5, 2026 report beat the EPS estimate by 2.99%, and the share price fell 0.99% in the first session after it.
Source: Earnings report, August 5, 2026New analyst coverage ›
Barclays started coverage at Equal-Weight on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026
- Keep an eye on the two closest levels. Above the price sits the 52-week high at $103.70, and below it the 50-day SMA at $95.06.
- A 14-day RSI of 55.5 sits in the neutral zone, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- The share price slipped 0.99% in the first session after the August 5, 2026 report. Over the 7 reports in our data, ZBH has beaten estimates 6 times.
ZBH's uptrend depends on the price holding above its 50-day average at $95.06 and its 200-day average at $91.53. A close below the 50-day would be the first sign of that trend weakening. If the price pulls back, the 50-day SMA at $95.06 is the first level it would meet.
Overhead, the next level for ZBH is the 52-week high at $103.70. The 14-day RSI reads 55.5, which sits in neutral territory between 40 and 60.
Technical indicators
Momentum and trend for ZBH, from its daily closes.
As of October 27, 2026, with ZBH at $96.08, its 14-day RSI is 55.5 (neutral territory), its 50-day simple moving average is $95.06 and its 200-day is $91.53.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What ZBH moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, ZBH's 1-year correlation of daily returns is +0.15 with S&P 500 (SPY), +0.02 with Nasdaq 100 (QQQ), -0.05 with Bitcoin (BTC) and -0.01 with gold (XAU).
ZBH price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
8 of 27 analysts rate it a buy or strong buy, 19 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $105.00 is 9.3% above the price.More buy ratings than three months ago ›
8 of 27 rate it a buy now, against 9 of 27 three months ago.
ZBH Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 22, 2026 | Argus Research | Reiterates | Buy |
| Oct 7, 2026 | Barclays | Initiates | Equal-Weight |
| Aug 10, 2026 | Canaccord Genuity | Maintains | Hold |
| Aug 7, 2026 | Truist Securities | Maintains | Hold |
| Aug 6, 2026 | RBC Capital | Maintains | Outperform |
| Aug 6, 2026 | Bernstein | Maintains | Market Perform |
As of October 27, 2026, 27 Wall Street analysts cover ZBH: 8 rate it a buy or strong buy, 19 a hold and 0 a sell or strong sell. Their 12-month price targets range from $93.00 to $130.00. The median ZBH price target is $105.00, 9.3% above the price of $96.08.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
ZBH trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ZBH trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from ZBH's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ZBH tends to move, against the market and on its own.
ZBH price history and drawdowns
ZBH's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 1.83% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 51.5%, from April 2021 to May 2026; the price is still 41.2% below that peak.Most 1-year holds ended higher ›
48% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $9,012, against $42,015 in the S&P 500 (SPY).
ZBH Drawdowns & Recovery
As of October 27, 2026, ZBH's worst peak-to-trough fall over the last 10 years with dividends reinvested was -51.5% (April 2021 to May 2026); it is still 41.2% below that peak, and 48% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ZBH in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ZBH trailed the S&P 500 over this period: $9,011.89 against $42,015.
A $10,000 investment in ZBH in October 2016 would be worth about $9,012 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ZBH, and which have not.
Strongest month, July: an average of +5.55%, up in 7 of 10 years.
Weakest month, May: an average of -3.82%, up in 1 of 10 years.
This month, October: has averaged -1.50%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ZBH's strongest calendar month has been July (average +5.55%, up in 7 of 10 years) and its weakest May (average -3.82%, up in 1 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
ZBH stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ZBH, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in ZBH today could grow to about $10,852 by 2030 in the base case, with a 90th-percentile outcome near $22,780 and a 10th-percentile outcome around $5,169. The simulation models price only; at today's 1.00% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
ZBH Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $104 for ZBH by 2030 in the base case, from $96.08 today (1.1x over 4 years). The 10th-percentile path ends near $49.67. These are outcomes of a Monte Carlo simulation run on ZBH's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $67.68 | $98.06 | $142 | |
| 2028 | $59.25 | $100 | $169 | |
| 2029 | $53.75 | $102 | $194 | |
| 2030 | $49.67 | $104 | $219 |
Method: a lognormal simulation of ZBH's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
ZBH insider trading
What the people running the company have bought and sold.
ZBH insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought ZBH shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 27, 2026, ZBH insiders reported 10 open-market sales worth $2.2M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Gary Craig Campbell
Officer
|
Grant | 3.6K | - |
| Sep 11, 2026 | Kevin R Thornal
Officer
|
Sell | 5.7K | $529.0K |
| Sep 4, 2026 | Chad F Phipps
Officer
|
Sell | 3.0K | $295.1K |
| Jul 31, 2026 | Kevin R Thornal
Officer
|
Grant | 10.0K | - |
| May 29, 2026 | Sang Yi
Officer
|
Sell | 5.0K | $413.2K |
| Apr 1, 2026 | Jehanzeb Noor
Officer
|
Grant | 6.6K | - |
| Mar 12, 2026 | Lori Winkler
Officer
|
Sell | 2.7K | $250.8K |
| Mar 6, 2026 | Chad F Phipps
Officer
|
Grant | 6.8K | - |
| Mar 6, 2026 | Paul A Stellato
Officer
|
Grant | 2.0K | - |
| Mar 6, 2026 | Ivan Tornos
Chief Executive Officer
|
Grant | 34.7K | - |
| Mar 6, 2026 | Suketu P Upadhyay
Chief Financial Officer
|
Grant | 14.8K | - |
| Mar 6, 2026 | Zuilen Wilfred Van
Officer
|
Grant | 7.0K | - |
| Mar 6, 2026 | Lori Winkler
Officer
|
Grant | 5.6K | - |
| Mar 6, 2026 | Sang Yi
Officer
|
Grant | 9.4K | - |
| Feb 25, 2026 | Chad F Phipps
Officer
|
Grant | 2.6K | - |
| Feb 25, 2026 | Paul A Stellato
Officer
|
Grant | 820 | - |
| Feb 25, 2026 | Ivan Tornos
Chief Executive Officer
|
Grant | 19.1K | - |
| Feb 25, 2026 | Suketu P Upadhyay
Chief Financial Officer
|
Grant | 6.4K | - |
| Feb 25, 2026 | Zuilen Wilfred Van
Officer
|
Grant | 3.2K | - |
| Feb 25, 2026 | Lori Winkler
Officer
|
Grant | 2.3K | - |
| Feb 25, 2026 | Sang Yi
Officer
|
Grant | 2.8K | - |
| Feb 20, 2026 | Chad F Phipps
Officer
|
Grant | 2.2K | - |
| Feb 20, 2026 | Paul A Stellato
Officer
|
Grant | 701 | - |
| Feb 20, 2026 | Ivan Tornos
Chief Executive Officer
|
Grant | 16.0K | - |
| Feb 20, 2026 | Suketu P Upadhyay
Chief Financial Officer
|
Grant | 5.4K | - |
| Feb 20, 2026 | Zuilen Wilfred Van
Officer
|
Grant | 2.5K | - |
| Feb 20, 2026 | Lori Winkler
Officer
|
Grant | 1.8K | - |
| Feb 20, 2026 | Sang Yi
Officer
|
Grant | 2.4K | - |
| Feb 12, 2026 | Sang Yi
Officer
|
Sell | 1.0K | $96.5K |
| Nov 28, 2025 | Lori Winkler
Officer
|
Grant | 179 | - |
| Nov 10, 2025 | Suketu P Upadhyay
Chief Financial Officer
|
Grant | 10.6K | - |
| Sep 11, 2025 | Sang Yi
Officer
|
Sell | 1.2K | $124.3K |
| Sep 8, 2025 | Lori Winkler
Officer
|
Sell | 1.5K | $156.2K |
| Aug 29, 2025 | Paul A Stellato
Officer
|
Grant | 1.3K | - |
| Aug 18, 2025 | Lori Winkler
Officer
|
Sell | 1.5K | $153.7K |
| Jul 1, 2025 | Zuilen Wilfred Van
Officer
|
Grant | 2.6K | - |
| Jun 13, 2025 | Sang Yi
Officer
|
Sell | 800 | $74.0K |
| Jun 11, 2025 | Sang Yi
Officer
|
Sell | 1.0K | $95.0K |
| May 30, 2025 | Paul A Stellato
Officer
|
Grant | 626 | - |
Source: TwelveData, from SEC Form 4 filings
ZBH stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.